Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases

Summary: Background & Aims: Higher serum bile acid levels are associated with an increased risk of cirrhosis and liver-related morbidity and mortality. Herein, we report secondary analyses of aldafermin, an engineered analogue of the gut hormone fibroblast growth factor 19, on the circulati...

Full description

Bibliographic Details
Main Authors: Arun J. Sanyal, Lei Ling, Ulrich Beuers, Alex M. DePaoli, Hsiao D. Lieu, Stephen A. Harrison, Gideon M. Hirschfield
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:JHEP Reports
Subjects:
Non-alcoholic steatohepatitis
Primary sclerosing cholangitis
Fibrogenesis
Fibroblast growth factor
Bile acid synthesis
Pro-C3
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555921000318

Internet

http://www.sciencedirect.com/science/article/pii/S2589555921000318

Similar Items